Brief: Tracon Pharmaceuticals Announces Fast Track Designation By The FDA For Envafolimab For The Treatment Of The Soft Tissue Sarcoma Subtypes Of Ups And Mfs
14/09/2022 13:57
Sept 14 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION BY
THE
FDA FOR ENVAFOLIMAB FOR THE TREATMENT OF THE SOFT TISSUE SARCOMA
SUBTYPES OF UPS AND MFS
* TRACON PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION BY
THE
FDA FOR ENVAFOLIMAB FOR THE TREATMENT OF THE SOFT TISSUE SARCOMA
SUBTYPES OF UPS AND MFS
Source text for Eikon: ID:nGNX3sNYkz
Further company coverage: TCON.O
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants